OxyContin Sales Data
Rank 19 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows OxyContin U.S. retail sales in Q4 2013 compared to previous quarters.
Date Range | Sales Rank | Sales ($000) | Units (000) | ||
---|---|---|---|---|---|
Q4 2013 | 19 | $585,482 | -2.91% | 1,048 | -1.87% |
Q3 2013 | 19 (![]() |
$603,048 | -3.01% | 1,068 | -3.52% |
Q2 2013 | 17 (![]() |
$621,785 | -4.71% | 1,107 | -5.87% |
Q1 2013 | 15 (![]() |
$652,536 | -2.38% | 1,176 | -5.47% |
Q4 2012 | 14 (![]() |
$668,415 | -1.69% | 1,244 | -0.72% |
Q3 2012 | 13 (![]() |
$679,924 | -0.55% | 1,253 | 0.16% |
Q2 2012 | 15 (![]() |
$683,693 | 3.14% | 1,251 | 0.16% |
Q1 2012 | 18 (![]() |
$662,876 | -1.05% | 1,249 | -2.35% |
Q4 2011 | 17 (![]() |
$669,915 | -2.58% | 1,279 | -1.69% |
Q3 2011 | 19 (![]() |
$687,676 | -5.33% | 1,301 | -4.69% |
Q2 2011 | 17 | $726,420 | 2.82% | 1,365 | -1.02% |
Q1 2011 | 17 | $706,496 | n/a | 1,379 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.